10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
There was no good news from the results of AstraZeneca’s Phase III EAGLE trial, although the fact that the failure did not seem that important was good news in itself. 10 December 2018
New York’s Bristol-Myers Squibb has agreed terms for a collaboration with Vedanta Biosciences, an affiliate of London-listed PureTech Health. 10 December 2018
Swiss pharmaceutical and biotech ingredient supplier Lonza has entered into an agreement with GE Healthcare under which the latter will deliver a biologics facility to Lonza in Guangzhou, China. 10 December 2018
Following the previously-announced plans of John Milligan to step down from the top post by year-end, US biotech major Gilead Sciences has named Daniel O'Day as chairman and chief executive, effective March 1, 2019. 10 December 2018
Following its acceptance in the UK’s Cancer Drug Fund in October, the medicines cost-effectiveness watchdog has now agreed to the regular NHS England funding of Yescarta (axicabtagene ciloleucel). 7 December 2018
Johnson & Johnson subsidiary Actelion has agreed to pay $360 million to resolve claims that it illegally used a foundation as a conduit to pay the co-pays of thousands of Medicare patients taking Actelion’s pulmonary arterial hypertension drugs, in violation of the False Claims Act, the US Department of Justice announced yesterday. 7 December 2018
Giving women palbociclib – already hailed as a major step forward in treating advanced breast cancer – alongside hormone therapy had a much greater effect on cell growth than the hormone treatment alone. 6 December 2018
US biotech Biogen has exercised its option to obtain from Ionis Pharmaceuticals a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067 (IONIS-SOD1RX), an investigational treatment for amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutations. 6 December 2018
UK-based C4X Discovery Holdings and e-therapeutics, a network-driven drug discovery (NDD) company, have updated their collaboration (announced May 1, 2018) to identify novel intervention strategies for the potential treatment of Parkinson’s disease (PD). 6 December 2018
UK-based rare and specialty diseases specialist Mereo BioPharma and US oncology focused OncoMed Pharmaceuticals today announce the proposed combination of the companies. 5 December 2018
Combining the AbbVie and Janssen drug Imbruvica (ibrutinib) with Roche’s Rituxan (rituximab) brings improved survival compared to a chemo-immunotherapy regimen in previously untreated and younger chronic lymphocytic leukemia (CLL) patients. 5 December 2018
Following the news on Monday (December 3) that UK pharma major GlaxoSmithKline (LSE: GSK) has struck a deal to purchase USA-based Tesaro (Nasdaq: TSRO) for $5.1 billion, GlobalData pharma analyst Paul Jeng offers his view on the company’s prospects. 5 December 2018
US biotech firm Revance Therapeutics saw its shares leap 19.5% to $24.91 by close of trading Tuesday, after it announced a licensing deal for its Botox rival (RT002 and some positive new clinical data for the investigational compound. 5 December 2018
Swedish Orphan Biovitrum and Novimmune have presented positive data from a pivotal Phase II/III study of Gamifant (emapalumab-lzsg) at the annual meeting of the American Society of Hematology. 5 December 2018
The US Food and Drug Administration has accepted the supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES-SCLC). 5 December 2018
Gilead Sciences has received approval from China’s National Medical Products Administration (NMPA) for Harvoni (ledipasvir 90mg/sofosbuvir 400mg) for the treatment of chronic hepatitis C virus (HCV) genotype 1-6 infection in adults and adolescents aged 12 to 18 years. 5 December 2018
Belgo-Dutch biotech argenx yesterday announced an exclusive, global collaboration and license agreement for cusatuzumab (ARGX-110), adding to its lucrative deal in the summer with AbbVie (NYSE: ABBV), with the news sending its share leaping 13% to 10.90 euros by close of trading on Monday. 4 December 2018
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024